Nationwide Availability of Cotempla XR-ODT for ADHD Announced

By October 02, 2017

Cotempla XR-ODT is a Schedule II controlled substance and is supplied as 8.6mg, 17.3mg, and 25.9mg strength orally-disintegrating tablets in cartons containing 5 blister cards of 6 tablets each.

Adzenys ER Approved for the Treatment of ADHD

By September 18, 2017

Adzenys ER is a once-daily extended-release liquid that does not need to be reconstituted or refrigerated.

Over 1 Million ADHD Patches Recalled Due to Liner Defect

By September 12, 2017

This error can make it difficult for patients and caregivers to remove the liners from the Daytrana patches.

Cotempla XR-ODT Available for Pediatric ADHD

By September 08, 2017

Cotempla XR-ODT contains methylphenidate, a central nervous system (CNS) stimulant.

FDA to Review Novel ADHD Treatment Dasotraline

By August 31, 2017

Two year-long studies assessing safety of dasotraline in children, adolescent and adult ADHD patients found the treatment to be generally well tolerated.

Neuroanatomic Abnormalities Identified in Those at High Risk for Autism

August 09, 2017

"In two genetically related cohorts at high risk for autism spectrum disorder, reciprocal neuroanatomic abnormalities were found and determined to be associated with cognitive and behavioral impairments," the authors write.

Treatment Shows Efficacy in Binge Eating Disorder

August 04, 2017

In both studies, more participants on LDX versus placebo were categorized as improved on the Clinical Global Impressions-Improvement starting at week one.

ADHD Med Adherence and Long-Term Substance Abuse Risk Examined

July 25, 2017

Patrick Quinn, PhD, of Indiana University Bloomington, and colleagues looked at data from 2,993,887 Americans with ADHD.

Maternal Antidepressant Use May Contribute to Offspring Autism

July 21, 2017

"Importantly, the absolute risk of autism was small, and, hypothetically, if no pregnant women took antidepressants, the number of cases that could potentially be prevented would be small," wrote the authors of the study.

PANS/PANDAS Treatment Guidelines Released

By July 20, 2017

"Immunomodulatory therapy should be considered early, because NSAIDs or a short course of oral corticosteroids may be sufficient for symptom remission in recent-onset cases, whereas those with long-standing symptoms often require more intensive and prolonged immunotherapeutic interventions," the authors write.

Mydayis Approved for the Treatment of ADHD

By June 21, 2017

Study data showed treatment with Mydayis significantly improved ADHD symptoms, as assessed by the ADHD-RS-IV and the Permanent Product Measure of Performance (PERMP), in both adolescents and adults.

Long-Acting, Orally-Disintegrating Tabs Approved for ADHD

By June 20, 2017

Patients using Cotempla XR-ODT showed a significant improvement in ADHD symptom control vs. placebo across the classroom day.

FDA Greenlights First Generic Version of ADHD Med

By May 31, 2017

Apotex, Teva, Aurobindo Pharma, and Glenmark are among the first companies to gain approval to market Atomoxetine Capsules in various strengths.

Parent-Mediated Intervention for At-Risk Autism Infants Shows Promise

May 12, 2017

Parents used this information to improve their baby's attention, communication, early language development, and social engagement.

ADHD Med Use May Help Cut Car Crashes

By May 10, 2017

The risk of motor vehicle crash for male patients was reduced by 38% during the months when medication was taken, compared to the months when it was not.

Novel DNRI Agent Improves ADHD Symptoms in Study

By April 21, 2017

Study data revealed children taking dasotraline 4mg daily had statistically significant and clinically meaningful improvement vs. placebo on the primary endpoint.

Does Prenatal Antidepressant Exposure Up Risk of ADHD, Autism?

By April 18, 2017

Autism spectrum disorder was diagnosed by age 15 in 5.28% of exposed vs. 2.14% of unexposed babies; 12.63% of exposed vs. 5.46% of unexposed babies were diagnosed with ADHD by age 15.

Vyvanse Available in Chewable Tablet Formulation

By April 14, 2017

The Food and Drug Administration initially approved the chewable tablet formulation in January 2017.

FDA Warns Against Products Claiming to Cure Autism

By April 12, 2017

The FDA has warned and/or taken action against a number of companies that have made improper claims about the intended use of their products in relation to treating autism or symptoms of autism.

VIDEO: Certain Drugs May Improve Cognitive Abilities in Chess Players

March 10, 2017

To examine any potential cognitive improvement, researchers conducted a crossover study of modafinil, methylphenidate, caffeine and placebo.

Sleep Interventions Reviewed for Children with ASD

By March 09, 2017

Researchers reviewed five interventions, included melatonin, drug therapy other than melatonin, alternative therapies (ie, massage, aromatherapy, multivitamin/iron supplementation), behavioral interventions and parent education/education programs.

Insecticide Exposure Linked to Behavioral Problems in Children

March 03, 2017

Behavioral disorders seen in 6-year-old children exposed in utero to pyrethroid insecticides

Is ADHD a Disorder of the Brain?

February 17, 2017

Through the formation of the international ENIGMA ADHD Working Group, researchers aimed to address weaknesses of previous imaging studies and investigate whether there are structural differences in the brain of those with ADHD.

Should Licorice Consumption During Pregnancy Be Avoided?

By February 03, 2017

Licorice consumption during pregnancy has been linked to lower IQ, poorer memory, and attention deficit hyperactivity disorder (ADHD)-type problems in offspring.

Psychostimulants Assessed as Possible Bulimia Nervosa Treatment

February 02, 2017

For select patients, psychostimulants may be beneficial for treating bulimia nervosa, according to a study of six cases published online January 23 in the Journal of Clinical Pharmacology.

Adherence to Mediterranean Diet May Lower ADHD Risk

January 31, 2017

Children who follow a Mediterranean diet may be less likely to have attention-deficit/hyperactivity disorder (ADHD), according to a study published online January 30 in Pediatrics.

Could Fecal Microbiota Transplant Benefit Autistic Children?

January 30, 2017

A new approach to alter the gut microbiome and virome may be an effective treatment for children with autism spectrum disorder (ASD), according to research published online January 23 in Microbiome.

Tablet Splitting and Liquid Dosing: Factors that Influence Accuracy

By January 24, 2017

Researchers sought to determine factors that influence accurate tablet splitting and liquid dosing by patients as compared to healthcare professionals.

Do Pre-Existing Psychiatric Conditions Impact Opioid Use?

By December 29, 2016

Study authors reported evidence of greater opioid receipt among commercially insured patients with a wide range of psychiatric conditions.

Drug, Therapy Combo Benefits TBI Patients with Cognitive Problems

By November 28, 2016

The findings, though preliminary, suggest that combined treatment with MAAT and methylphenidate can improve attention, episodic and working memory, and executive functioning following traumatic brain injury.